Sullivan Mark, Chief Legal Officer at Definium Therapeutics ($DFTX), made four open market sales of company shares over the last year, totaling nearly $381,000. His most recent sale occurred on December 26, 2025. These transactions rank 7,053rd out of 11,678 individual insiders, well below the average sale amount of $8.6 million across 6 transactions per insider. Sullivan Mark recorded no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 25, 2026 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | S | Common Shares | 10702 | $18.47 | 271,079.0000 | 98,509,279 | 3.80% | 0.01% |
| Feb. 3, 2026 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | A | Common Shares | 125000 | $0.00 | 407,576.0000 | 98,509,279 | 44.24% | 0.13% |
| Dec. 26, 2025 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | S | Common Shares | 11276 | $13.15 | 282,576.0000 | 98,509,279 | 3.84% | 0.01% |
| Sept. 25, 2025 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | S | Common Shares | 11278 | $9.77 | 293,852.0000 | 75,368,359 | 3.70% | 0.01% |
| June 25, 2025 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | S | Common Shares | 11491 | $6.80 | 305,130.0000 | 75,368,359 | 3.63% | 0.02% |
| March 25, 2025 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | S | Common Shares | 6576 | $6.74 | 316,621.0000 | 75,368,359 | 2.03% | 0.01% |
| March 12, 2025 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | A | Common Shares | 150000 | $0.00 | 323,197.0000 | 75,368,359 | 86.61% | 0.20% |
| Dec. 26, 2024 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | S | Common Shares | 4519 | $7.43 | 173,197.0000 | 0 | 2.54% | 0.00% |
| Sept. 25, 2024 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | S | Common Shares | 4430 | $5.98 | 177,716.0000 | 0 | 2.43% | 0.00% |
| June 25, 2024 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | S | Common Shares | 17854 | $7.22 | 182,146.0000 | 0 | 8.93% | 0.00% |
| Feb. 27, 2024 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | A | Stock Option (Right to Buy) | 125000 | $0.00 | 125,000.0000 | 0 | 9999.99% | 0.00% |
| April 13, 2023 | Definium Therapeutics, Inc. | $DFTX | Sullivan Mark | Chief Legal Officer | A | Common Shares | 200000 | $0.00 | 200,000.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2023 | Carisma Therapeutics Inc. | $CARM | Sullivan Mark | General Counsel & Secretary | M | Common Stock | 113175 | $0.59 | 423,530.0000 | 0 | 36.47% | 0.00% |
| March 2, 2023 | Carisma Therapeutics Inc. | $CARM | Sullivan Mark | General Counsel & Secretary | S | Common Stock | 44879 | $0.59 | 378,651.0000 | 0 | 10.60% | 0.00% |
| March 2, 2023 | Carisma Therapeutics Inc. | $CARM | Sullivan Mark | General Counsel & Secretary | S | Common Stock | 100978 | $0.59 | 198,716.0000 | 0 | 33.69% | 0.00% |
| March 2, 2023 | Carisma Therapeutics Inc. | $CARM | Sullivan Mark | General Counsel & Secretary | M | Common Stock | 185000 | $0.59 | 383,716.0000 | 0 | 93.10% | 0.00% |
| March 2, 2023 | Carisma Therapeutics Inc. | $CARM | Sullivan Mark | General Counsel & Secretary | S | Common Stock | 73361 | $0.59 | 310,355.0000 | 0 | 19.12% | 0.00% |
| Feb. 21, 2023 | Carisma Therapeutics Inc. | $CARM | Sullivan Mark | General Counsel & Secretary | S | Common Stock | 39831 | $0.59 | 299,694.0000 | 0 | 11.73% | 0.00% |